Endometrial Protection and Systemic Symptom Support

This medication is commonly used across conditions characterized by periods of heightened symptoms, such as the menopausal transition, where estrogen therapy is being administered. Its role is to provide supportive endometrial protection for postmenopausal women with an intact uterus. This function is applied in addressing the risk of abnormal uterine thickening (hyperplasia), providing supportive benefit and assisting with maintaining functional stability in the context of systemic estrogen use. Furthermore, it helps manage accompanying symptoms related to systemic imbalance, such as sleep disturbances and mood fluctuations.

Regulation of Menstrual Cycles and Reproductive Health

Vasclor is applied across domains where additional symptomatic support is needed to address a systemic imbalance of sex hormones. It is specifically used to treat secondary amenorrhea and helps patients with cyclical regulation, which is relevant in conditions involving episodic or fluctuating manifestations of hormone deficiency. Additionally, micronized progesterone is commonly used to help with luteal phase support in assisted reproductive technology (ART), and may assist with providing supportive relief that helps patients cope more steadily during periods of heightened discomfort.

---

Quick Fact: Relief for Cyclical Disruption Vasclor assists with maintaining functional stability by supporting a predictable menstrual rhythm in women with absent or irregular periods.

Who Can and Cannot Use Vasclor? (Micronized Progesterone)

The eligibility for Vasclor is strictly defined by regulatory documents, distinguishing between approved populations, restricted use, and absolute contraindications.

Approved Populations and Use Restrictions

Vasclor is approved for use in adult women who are postmenopausal with an intact uterus (as adjunct to estrogen therapy) or those with secondary amenorrhea. Safety and efficacy have not been established in the pediatric population, and the medicine is not indicated in children. Use in women who are breastfeeding is not recommended.

Absolute Contraindications

Vasclor is contraindicated and must not be used in patients with specific medical histories and conditions, including:

• Severe liver dysfunction or active liver disease.
• A personal history of arterial or venous thromboembolic disorders.
• Known or suspected hormone-dependent malignancies (e.g., breast or genital tract cancer).
• Undiagnosed abnormal genital bleeding.
• Known hypersensitivity to progesterone, excipients, or components like peanut or soya (for oral formulations).

Use requires careful monitoring in patients with renal dysfunction or mild to moderate hepatic dysfunction.

Interactions with other medicines and products

The interaction profile for Vasclor (micronized progesterone) is largely defined by its metabolism and its effect on other drugs' concentrations, as documented by regulatory bodies.

---

Pharmacokinetic Interactions

Interaction Type	Interacting Substances	Official Outcome
Reduced Exposure (CYP3A4 Induction)	Rifampicin, Antiepileptic agents (Phenytoin, Carbamazepine), Barbiturates, Griseofulvin, and St. John’s Wort (herbal product).	Increase progesterone metabolism, leading to reduced plasma concentration of Vasclor.
Increased Exposure (CYP3A4 Inhibition)	Strong CYP3A4 inhibitors, such as Ketoconazole and Ritonavir.	Decrease progesterone metabolism, leading to increased plasma concentration of Vasclor.

---

Pharmacodynamic and Timing Constraints

Co-administration with antidiabetic agents may necessitate dosage adjustments, as progesterone is officially documented to potentially reduce glucose tolerance. Progesterone also increases the plasma concentrations of certain co-administered drugs, including the immunosuppressant Ciclosporin and the muscle relaxant Tizanidine.

For the oral capsule formulation, a timing constraint is officially documented: it must not be taken with food. Co-administration with food is shown to significantly increase the systemic bioavailability of the medication. Additionally, the drug is formally contraindicated in patients with acute or history of severe liver disease due to the potential for accumulation.

Vasclor's active ingredient is micronized progesterone, a synthetic form of the endogenous steroid hormone progesterone. It is selectively accumulated at the uterine endometrium following vaginal administration. Progesterone functions as an agonist by binding to and activating the intracellular Progesterone Receptors (PR), which are members of the nuclear/steroid hormone receptor superfamily.

Upon ligand binding, the activated PR dimerizes, translocates to the nucleus, and acts as a ligand-dependent transcription factor. This complex binds to specific Progesterone Response Elements (PREs) in the promoter regions of target genes, thereby modulating their transcription. The molecular consequence is the conversion of the proliferative endometrium into a secretory endometrium. This involves a sequence of intracellular changes in the endometrial cells, including decreased proliferation, the development of complex uterine glands, and an increase in vascularity and stromal hydration.

At the system level, this modulation of gene expression induces the requisite differentiation and maturation of the endometrial lining, preparing the tissue for subsequent cellular and molecular events. Furthermore, progesterone provides negative feedback to the hypothalamus-pituitary-ovarian axis, which modulates the secretion of Gonadotropins, specifically Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), influencing the endogenous reproductive cycle.

Vasclor is administered via specific, approved routes of administration and defined schedules. The medication is available as an oral capsule and as a vaginal insert or gel, depending on the established regimen.

Official Dosing Regimens and Administration Rules

Usage is primarily structured around fixed, time-limited schedules. For postmenopausal women with an intact uterus who are receiving estrogen therapy, the oral dose is typically 200 mg administered once daily for 12 consecutive days of a scheduled 28-day cycle. Conversely, for the treatment of secondary amenorrhea, the official dosing involves 400 mg taken once daily for 10 days.

Administration Rule	Labeled Context
Oral Intake Timing	Oral capsules must be taken at bedtime and generally without food to account for absorption patterns.
Capsule Integrity	The oral capsule must be swallowed whole with water and must not be crushed, chewed, or divided.
Hepatic Function	Dosing may require adjustment, or the medicine may be restricted, in cases of significant hepatic (liver) impairment.

Adherence to these procedural constraints is essential for the prescribed application. For instance, if an oral dose is missed, the standard approach is to simply take the next scheduled dose and resume the regular timing, without attempting to double the amount. This structured approach dictates the precise use patterns across different official contexts.

Research Evidence / Overview of Studies for Vasclor

This overview summarizes the available research and clinical studies for Vasclor (micronized progesterone) as reported in official and peer-reviewed scientific literature. The purpose is to describe the types of research conducted, the outcomes monitored, and where limitations or uncertainties exist in the evidence base.

---

Evidence for Endometrial Protection

Research has focused on the use of micronized progesterone in postmenopausal women who have an intact uterus and are receiving estrogen therapy. Research has primarily involved large Randomized Controlled Trials (RCTs) and systematic reviews. The main focus was on histological outcomes, monitoring the rate of endometrial hyperplasia (abnormal cell growth) confirmed through tissue samples (biopsies). Findings describe patterns observed in the studies related to the incidence of hyperplasia compared across the different study groups. However, evidence remains limited when comparing its performance directly against all other synthetic forms of progesterone used for this purpose.

Evidence for Reproductive Health Support (ART)

A large volume of evidence exists, including numerous RCTs and comprehensive Meta-analyses, exploring the use of micronized progesterone for luteal phase support in women undergoing Assisted Reproductive Technology (ART) procedures like IVF. The main outcomes studied were objective measures including clinical pregnancy rates and live birth rates. Research describes its use as a standard component of hormonal support in ART settings, and studies monitored the outcomes related to spontaneous abortion incidence. Research explored whether differences in outcomes were observed when comparing different routes of administration (e.g., vaginal vs. oral).

Key Limitations and Areas of Uncertainty

Overall, the evidence quality varies across studies, particularly for subjective outcomes like sleep or mood. Long-term data beyond the initial follow-up periods are not fully established for all indications. Furthermore, comparative evidence is lacking between micronized progesterone and synthetic progestins for all indications. Research highlights that study findings describe group patterns, not personal outcomes, and data are still emerging to determine the optimal timing, dose, and route of administration across all clinical settings.

Key Studies & References Micronized progesterone, progestins, and menopause hormone therapy - Narrative Review (Supporting Endometrial/Breast Safety Context)

Common questions about Vasclor (FAQ)

---

Q: How quickly does Vasclor usually start working?

Regulatory pharmacokinetic data describes how the medication is absorbed by the body. According to the official product information, the maximum amount of the active ingredient in the bloodstream is typically reached within 1.5 to 3 hours after taking the oral capsule.

Q: What over-the-counter medicines might interact with Vasclor?

Official drug interaction reports focus on substances that can change how your body processes the medicine. Regulatory documents describe that the herbal product St. John’s Wort can increase the metabolism of the active ingredient, which may lead to reduced levels of the medication in the blood.

Q: Does Vasclor interact with caffeine or alcohol?

The medication is documented to increase the risk of certain side effects, such as dizziness or drowsiness, when it is consumed with alcohol. Some official health sources suggest that limiting caffeine intake has been examined as a potential strategy to lessen symptoms like hot flushes.

Q: Can Vasclor affect sleep patterns or cause insomnia?

Sleep-related effects are described in regulatory documents. While common effects include drowsiness (somnolence) and fatigue, official adverse reaction reports also specifically include sleep problems or trouble sleeping (insomnia) as possible occurrences.

Q: Are there any long-term safety concerns associated with Vasclor?

When the medication is used in combination with estrogen therapy, official safety reports describe patterns of increased risks of serious health issues over time. These documented risks include blood clots, stroke, heart attack, and certain types of cancers.

Q: What happens if I forget to take a dose of Vasclor?

Official guidance for the oral capsule formulation describes a procedure to take the next scheduled dose and resume the regular timing. It is advised in regulatory documents not to attempt to double the amount for a missed dose. Instructions for other forms of the medication should be confirmed with the prescribing information.

Q: Is Vasclor a long-term treatment or short-term?

The usage is structured around short, repeating, cyclic schedules (e.g., 10 or 12 days). Clinical studies have examined the medication’s use over periods lasting up to 36 months, according to official prescribing information.

Q: What should I know about stopping Vasclor?

Official guidance describes that abruptly stopping the medication is not advised. Any change to a prescribed schedule must be discussed with a healthcare professional.

Q: Can Vasclor be taken with other prescriptions for chronic conditions?

Official documents describe potential interactions between this drug and several prescription medications. These include some antifungals, antidiabetic agents, and drugs that affect liver enzymes (CYP3A4). A complete list of documented interactions is available in the official prescribing information.

Q: Are there specific laboratory tests required when using Vasclor?

Official documentation requires careful monitoring for patients with certain underlying conditions, such as renal (kidney) or hepatic (liver) impairment and diabetes. Specific testing is determined based on the documented need for monitoring.

Q: Does Vasclor affect blood sugar levels?

Regulatory information documents the possibility of the metabolic adverse reaction hyperglycemia (elevated blood sugar levels). Monitoring for changes in glucose tolerance is described as necessary for patients with diabetes.

Q: Why is consistency important when taking Vasclor?

Official prescribing information emphasizes consistency when the medication is used in fixed, scheduled cycles. This ensures that the intended endometrial protection is achieved and maintained, as defined in clinical protocols.

Q: Is Vasclor a type of blood pressure medicine?

No, the medication is not classified as a blood pressure medicine. It is officially classified as a progestogen hormone. Its approved uses are related to hormone restoration and the protection of the uterine lining, not the management of blood pressure.

Q: Is Vasclor considered a preventative medication?

Yes, for one of its official uses. The drug is indicated for the prevention of endometrial hyperplasia (abnormal cell growth) in postmenopausal women with an intact uterus who are receiving estrogen therapy.

Q: Does Vasclor cause weight gain or loss?

Weight changes have been reported in clinical use. Official safety information lists weight gain as a possible adverse effect associated with this medication.

Q: What is the difference between Vasclor and other similar medications?

The medication contains micronized progesterone, which is structurally bioidentical to the progesterone hormone naturally produced by the human body. This composition is one feature that distinguishes it from other synthetic forms of progesterone known as progestins.

Q: Is there a generic version of Vasclor available?

The active ingredient in this drug is progesterone. The generic version, micronized progesterone capsules, is widely available and used as a bioequivalent alternative, according to official drug listings.

Q: Can Vasclor be taken before or after a meal?

Official prescribing information states that the oral capsule formulation has a constraint that it must not be taken with food. This is because co-administration significantly increases the amount of the drug absorbed into the systemic circulation.

Q: Are there common signs of too much Vasclor in the system?

Official safety information documents serious adverse reactions, such as sudden vision changes, severe headache, or slurred speech. The occurrence of these serious symptoms is noted in regulatory safety information as requiring immediate medical attention.

Q: Does Vasclor have a high risk of drug dependency?

Official regulatory documents, including the section on drug abuse potential, do not classify this medication as having an abuse or dependency risk.

Q: Is Vasclor associated with any vision changes?

Regulatory safety information documents that vision changes have been reported. These include blurred vision and sudden partial or complete loss of vision, and are listed as potential serious adverse reactions.

Storage and Disposal Requirements for Vasclor

Vasclor (micronized progesterone capsules) must be stored under specific conditions to maintain stability, as required by regulatory authorities.

Storage Conditions

The medication must be kept at Controlled Room Temperature, typically between 15 C and 30 C (59 F and 86 F). The product must be protected from excessive moisture, heat, and light and kept from freezing.

• Container Rules: Store Vasclor in the original container and ensure it is tightly closed.
• Child Safety: Keep the medicine out of the reach and sight of children and store it in a secured location.

Disposal

Expired or unused Vasclor must be disposed of in accordance with local requirements. Do not flush the medication down a toilet or pour it into a drain, and do not dispose of it in a way that allows it to be released into the environment. Consult a pharmacist or an authorized local drug take-back program for proper disposal.